M. Walles, A. Connor and D. Hainzl * Pages 3463 - 3475 ( 13 )
Non-cleavable linkers are used in a number of different modalities for various reasons, such as linking an active drug moiety to half-life extending molecules, to groups that enable a specific tissue or cell targeting or to facilitate active uptake into target cells. Non-cleavable linkers do not have a designated weak point in their structure that can lead to cleavage by proteases, hydrolases or chemically by pH changes. Consequently, when designing a conjugate, the choice of a non-cleavable over a cleavable linker is usually a consequence of pursuing a certain mode of action where the stability of the complex is more important than a fast liberation of the active moiety.
Linkers of various length, polarity, stability and flexibility are used for different types of conjugates and the linker design is mostly driven by the particular purpose and desired mode of action. This article reviews non-cleavable linkers applied predominantly in Antibody Drug Conjugates (ADCs), and how they influence these conjugates in terms of ADME properties (absorption, distribution, metabolism and elimination) and safety.
Non-cleavable linker, Antibody-drug conjugate, Catabolism, Bystander activity, ADME, Polyethylene glycol.
Novartis Institute for Biomedical Research, 250 Massachusetts Ave, 1B-123, Cambridge, MA, Novartis Institute for Biomedical Research, 250 Massachusetts Ave, 1B-123, Cambridge, MA, Novartis Institute for Biomedical Research, 250 Massachusetts Ave, 1B-123, Cambridge, MA